Characteristic | Value |
---|---|
Age (years), median (range) | 83 (80.0–94.8) |
Sex (n), male/female | 45/19 |
Follow-up (months), median (range) | 39 (3.5–95.7) |
BMI (kg/m2), median (range) | 22.8 (16.7–29.4) |
BMI distribution (n), < 18.5/18.5–25.0/ > 25 kg/m2 | 5/48/11 |
ECOG PS (n), 0/1/2/3 | 28/19/11/6 |
Operability (n), yes/no | 16/48 |
GOLD stage (n), normal/I/II/III† | 24/18/13/4 |
FEV1.0 (L), median (range) † | 1.6 (0.7–2.7) |
History of lung operation (n), yes/no | 14/50 |
Charlson Comorbidity Index (n), 2/3/4/5/6/7/9 | 10/28/12/7/3/2/2 |
T stage (n), Tis/T1mi/T1a/T1b/T1c/T2a/T2b | 2/2/5/26/17/10/3 |
Maximum tumor diameter (cm), median (range) | 2.1 (0.8–4.1) |
ITV (mL), median (range) | 10.2 (1.1–51.8) |
PTV (mL), median (range) | 32.4 (9.6–110.6) |
Histology (n) | |
Adenocarcinoma | 43 |
Squamous cell carcinoma | 19 |
Unclassified NSCLC | 3 |
Tumor opacity (n), pure GGN/part solid GGN/solid | 2/18/45 |
Location (n), central/peripheral | 1/64 |
Location (n), left/right | 24/41 |
Location (n), upper lobe/middle lobe/lower lobe | 37/1/27 |
Prescribed dose (n) | |
48 Gy (isocenter) | 41 |
60 Gy (isocenter) | 6 |
48 Gy (D95) | 18 |